The Efficacy And Safety Of Herbal Medicine In Oncology: A Systematic Review

Bharat Raybhan Rakte, Komal More, Dr. D.K. Vir,Sandesh Damodhar Gangaler.
1) Student, 2) Associate professor,3) Principal, 4) Student, 5) Student
Department of Pharmaceutical Science and Technology.
Shree Goraksha College of Pharmacy & Research Centre, Chhatrapati Sambhaji Nagar, India

Abstract : Cancer is a multifactorial disease marked by uncontrolled cell growth and metastasis, remaining one of the leading causes of mortality worldwide. Conventional treatment methods such as chemotherapy, radiotherapy, and surgery have significantly improved survival but often result in severe side effects, high costs, and reduced patient tolerance. In contrast, herbal medicine has gained growing attention as a complementary and integrative approach in cancer therapy due to its effectiveness, affordability, and minimal toxicity. Medicinal plants contain diverse bioactive compounds such as alkaloids, flavonoids, terpenoids, and polyphenols, which exhibit strong anti-cancer, antioxidant, anti-inflammatory, and immunomodulatory properties. These phytoconstituents act through multiple mechanisms, including inhibition of tumor proliferation, induction of apoptosis, suppression of angiogenesis, and modulation of key molecular signaling pathways involved in carcinogenesis. Recent studies and clinical evidence suggest that combining herbal medicines with conventional therapies may enhance therapeutic efficacy, mitigate adverse effects, and improve patients' quality of life. However, challenges such as lack of standardization, variability in phytochemical content, and limited large-scale clinical validation continue to restrict their widespread application. Further research focusing on standardized formulations, safety profiles, and precise dosage optimization is essential to ensure efficacy and reliability. The integration of scientifically validated herbal medicines into modern cancer care could offer a more holistic, safe, and patient-centered approach to cancer management.

Keywords: Cancer, Herbal Medicine, Phytochemicals, Complementary Therapy, Anticancer, Natural Compounds

1. Introduction

Cancer is a multifaceted and heterogeneous group of diseases characterized by abnormal, uncontrolled cellular growth, tissue invasion, and the potential to metastasize to distant organs. It represents one of the most pressing global health challenges of the 21st century, contributing to millions of deaths annually despite major advances in medical science and technology. The pathogenesis of cancer involves a complex interplay of genetic mutations, epigenetic alterations, and environmental factors, which disrupt normal cellular signaling pathways and promote tumor initiation, progression, and resistance to apoptosis. According to global health statistics, cancer remains a leading cause of mortality worldwide, with incidence rates projected to rise due to aging populations, urbanization, and exposure to carcinogenic agents.

Conventional cancer treatments such as chemotherapy, radiotherapy, immunotherapy, and surgery have revolutionized oncology and improved survival outcomes for many patients. However, these therapies are often accompanied by substantial drawbacks, including severe toxicity, drug resistance, immunosuppression, nausea, hair loss, mucositis, organ damage, and overall deterioration in quality of life. Moreover, their high financial burden makes them less accessible in developing and resource-limited countries. These limitations have prompted researchers and clinicians to explore safer, more affordable, and integrative treatment options that can complement conventional therapies while minimizing adverse effects.

In this context, herbal medicine has gained increasing recognition as a promising complementary and alternative approach in cancer prevention and therapy. Medicinal plants are reservoirs of diverse bioactive phytochemicals, including alkaloids, flavonoids, terpenoids, polyphenols, glycosides, tannins, and saponins, many of which possess potent pharmacological activities relevant to cancer control. These compounds exhibit multifaceted biological effects such as antioxidant, anti-inflammatory, antiproliferative, pro-apoptotic, anti-angiogenic, and immunomodulatory properties. Unlike synthetic chemotherapeutic agents that often target a single molecular pathway, herbal compounds act on multiple targets simultaneously, thereby reducing the risk of drug resistance and offering a more holistic therapeutic approach.

Mechanistically, phytochemicals can inhibit tumor cell proliferation, induce apoptosis through mitochondrial and death receptor pathways, modulate cell cycle progression, and suppress angiogenesis and metastasis. For instance, curcumin from Curcuma longa downregulates NF-κB and STAT3 signaling pathways; resveratrol from grapes exerts strong antioxidant and anti-inflammatory effects; and epigallocatechin gallate (EGCG) from green tea modulates MAPK and PI3K/Akt signaling, contributing to the suppression of cancer cell growth. Moreover, herbal extracts often enhance the sensitivity of tumor cells to conventional chemotherapeutic drugs while protecting normal cells from cytotoxic damage, thus improving overall treatment outcomes.

Emerging evidence also suggests that the integration of herbal medicine with conventional cancer therapies can lead to synergistic effects. Combination treatments may enhance therapeutic efficacy, reduce side effects, prevent recurrence, and improve patient tolerance and survival rates. For example, studies have shown that herbal formulations used alongside chemotherapy can alleviate nausea, fatigue, and myelosuppression, thereby enhancing the patient's quality of life. Additionally, the antioxidant and immunostimulatory activities of certain herbs help in restoring the body's natural defense mechanisms, further supporting recovery.

Despite these promising developments, several challenges hinder the widespread adoption of herbal medicines in mainstream oncology. The lack of standardization in extraction methods, variability in phytochemical composition due to geographical and seasonal factors, absence of uniform quality control, and limited large-scale clinical trials pose significant barriers to clinical translation. Furthermore, issues such as herb-drug interactions, unclear pharmacokinetic profiles, and dosage inconsistencies must be systematically addressed to ensure safety and reproducibility.

To overcome these limitations, future research should emphasize scientific validation, pharmacological standardization, and regulatory framework development for herbal-based cancer therapies. Advanced analytical tools such as metabolomics, molecular docking, and high-throughput screening can help identify and characterize active phytoconstituents responsible for anticancer effects. Furthermore, the use of nanotechnology-based herbal formulations—such as nanoemulsions, liposomes, and polymeric nanoparticles—holds potential to enhance bioavailability, targeted delivery, and therapeutic precision of herbal compounds.

2. Objectives

The present study aims to provide a comprehensive understanding of the use of herbal medicine in cancer prevention and therapy The specific objectives of this review are outlined and explained as follows:

1. **To explore the role of herbal medicine as a complementary or alternative approach in cancer treatment.**

   This objective seeks to evaluate how herbal therapies can be integrated with conventional cancer treatments such as chemotherapy, radiotherapy, and immunotherapy. It also aims to understand the contribution of herbal formulations in enhancing therapeutic efficacy, minimizing toxicity, and improving patient quality of life.

2. **To identify commonly used anti-cancer herbs and their active phytochemicals.**

   The study aims to catalog key medicinal plants traditionally or scientifically recognized for their anti-cancer potential. It will identify their major bioactive constituents—such as alkaloids, flavonoids, terpenoids, and polyphenols—and their pharmacological significance in inhibiting tumor growth and metastasis.

3. **To understand the molecular mechanisms of herbal anti-cancer activity.**

This objective focuses on elucidating the molecular pathways and biological targets modulated by phytochemicals, suppression of tumor proliferation, modulation of oxidative stress, and regulation of cell signaling pathways like PI3K/Akt, MAPK, and NF-κB.

4. **To examine clinical evidence supporting herbal medicine in cancer therapy.**

The study aims to analyze available preclinical and clinical data demonstrating the therapeutic effectiveness of herbal preparations. It seeks to highlight clinical trials, case studies, and meta-analyses that validate the safety and efficacy of herbal medicines in cancer management.

5. **To assess the benefits and limitations of using herbal medicine in oncology.**

As low toxicity, affordability, and multi-targeted effects—and the challenges, including lack of standardization, limited clinical validation, and variability in phytochemical content, associated with the use of herbal therapies in cancer treatment.

6. **To discuss potential herb-drug interactions and safety concerns.**

The study aims to identify and analyze possible pharmacokinetic and pharmacodynamic interactions between herbal medicines and conventional drugs. It also seeks to assess toxicity profiles, contraindications, and safety measures essential for patient well-being during integrative therapy.

7. **To explore future trends in herbal-based anti-cancer drug development.**

This objective focuses on investigating emerging scientific innovations such as nanotechnology-based herbal formulations, molecular docking studies, and synthetic modification of natural compounds to enhance therapeutic potency, bioavailability, and target specificity.

8. **To promote awareness of integrative oncology approaches.**

The study intends to encourage awareness and acceptance of integrative medicine models that combine evidence-based herbal therapies with modern cancer treatments..

9. **To evaluate the effect of herbal medicines on chemotherapy-induced side effects.**

This it determine the potential of herbal remedies in alleviating treatment-associated complications such as nausea, fatigue, mucositis, immunosuppression, and organ toxicity, thereby improving patient tolerance and recovery outcomes.

10. **To provide guidelines for further research and clinical application of herbal medicine.**

The final objective is to establish a framework for future investigations focusing on standardization, clinical validation, dosage optimization, and regulatory policies. It also seeks to encourage the scientific integration of traditional knowledge into evidence-based modern oncology.

3. Classification of Anti-Cancer Herbs

Herbal medicines play a significant role in the prevention and treatment of cancer due to their wide range of bioactive phytochemicals that target multiple signaling pathways involved in carcinogenesis. Based on their primary mechanism of action, anti-cancer herbs can be broadly classified into several functional categories. Each category contributes uniquely to the inhibition of cancer progression, promotion of apoptosis, and modulation of tumor-related biological processes.



Figure 1: Classification of Anti-Cancer Herbs Based on Mechanism

3.1 Apoptosis Inducers

Apoptosis, or programmed cell death, is a vital process that eliminates damaged or abnormal cells. Cancer cells often evade apoptosis, enabling their uncontrolled proliferation. Certain herbal compounds have demonstrated the ability to reactivate apoptotic pathways in tumor cells through intrinsic (mitochondrial) and extrinsic (death receptor-mediated) mechanisms.

➢ **Key examples include:**

- **Curcumin** (Curcuma longa) – Promotes apoptosis by upregulating pro-apoptotic proteins such as Bax and downregulating anti-apoptotic proteins like Bcl-2. It also activates caspase-3 and caspase-9 pathways.
- **Resveratrol** (found in grapes and berries) – Induces apoptosis through modulation of p53, suppression of NF-κB signaling, and generation of reactive oxygen species (ROS).
- **Withaferin** A (Withania somnifera) – Exhibits potent cytotoxic effects by activating the mitochondrial pathway of apoptosis and inhibiting oncogenic transcription factors.

3.2 Anti-Proliferative Agents

Uncontrolled cell division is a hallmark of cancer. Anti-proliferative herbal agents act by interfering with DNA replication, cell cycle regulation, and mitotic activity, thereby reducing tumor growth and spread.

➢ **Key examples include:**

- **Epigallocatechin gallate (EGCG)** (Camellia sinensis, Green tea) – Inhibits cancer cell proliferation by blocking MAPK and PI3K/Akt signaling pathways, leading to growth arrest.
- **Quercetin** (found in onions, apples, and citrus fruits) – Modulates cyclin-dependent kinases (CDKs) and induces G1 phase arrest in cancer cells.

3.3 Angiogenesis Inhibitors

Angiogenesis, the process of new blood vessel formation, is critical for tumor growth and metastasis. By inhibiting angiogenic signaling, certain herbs restrict the supply of oxygen and nutrients to cancer cells, leading to tumor regression.

➢ **Key examples include:**

- **Ginseng** (Panax ginseng) – Contains ginsenosides that inhibit vascular endothelial growth factor (VEGF) signaling, thereby reducing tumor angiogenesis.
- **Garlic Extract** (Allium sativum) – Allicin and other sulfur compounds suppress angiogenic markers such as VEGF and matrix metalloproteinases (MMPs).

3.4 Immunomodulators

The immune system plays a crucial role in recognizing and eliminating malignant cells. Immunomodulatory herbs enhance the body's natural defense mechanisms by stimulating immune cell activity, increasing cytokine production, and improving immune surveillance.

Table 1 : Representative Anti-Cancer Herbs and Their Active Phytochemicals

Herbal Source	Active Phytochemical(s)	Mechanism of Action	Type of Cancer Studied
Curcuma longa	Curcumin	Apoptosis induction, NF-κB inhibition	Breast, Colon
Withania somnifera	Withaferin A	Mitochondrial apoptosis activation	Lung, Prostate
Camellia sinensis	EGCG	Cell cycle arrest, anti-angiogenic	Liver, Colon
Panax ginseng	Ginsenosides	VEGF inhibition, immune modulation	Gastric, Lung
Viscum album	Lectins, Viscotoxins	Immunostimulation, apoptosis	Breast, Colorectal

➢ **Key examples include:**

- **Mistletoe** (Viscum album) – Boosts immune response by increasing macrophage and natural killer (NK) cell activity; widely used as an adjunct therapy in Europe.
- **Astragalus** (Astragalus membranaceus) – Enhances T-cell and B-cell function and improves resistance against tumor growth.

3.5 Anti-Inflammatory and Antioxidant Herbs

Chronic inflammation and oxidative stress are closely linked to cancer initiation and progression. Herbal antioxidants neutralize free radicals and reactive oxygen species, while anti-inflammatory compounds suppress pro-tumorigenic signaling pathways.

➢ **Key examples include:**

- **Turmeric** (Curcuma longa) – Contains curcumin, a potent anti-inflammatory and antioxidant that inhibits COX-2, TNF-α, and NF-κB pathways.
- **Green Tea** (Camellia sinensis) – Rich in catechins that scavenge free radicals and protect DNA from oxidative damage.

4. Herbal Formulations for Cancer Management

Herbal medicines have emerged as an important component of integrative oncology, offering supportive, preventive, and therapeutic benefits. These medicines can be formulated in various dosage forms to enhance bioavailability, stability, patient compliance, and targeted drug delivery. Modern formulation techniques have transformed traditional herbal preparations into standardized and scientifically validated dosage forms, suitable either as standalone therapies or adjuncts to conventional cancer treatments. The type of formulation selected often depends on the nature of the active constituents, their solubility, pharmacokinetics, and therapeutic goals.

Herbal formulations for cancer management can broadly be classified into **oral, topical, parenteral, and novel drug delivery systems** as described below.

4.1 Oral Formulations

Oral administration remains the most preferred and convenient route for delivering herbal medicines, primarily due to its ease of use, patient acceptability, and suitability for chronic therapy. Several types of oral formulations are used in cancer management.

4.2 Capsules and Tablets

Capsules and tablets are among the most standardized and stable forms of herbal formulations. They typically contain **powdered plant extracts**, **dry granules**, or **standardized phytochemical isolates** compressed into solid dosage forms.

➢ **Examples of herbal ingredients:**

- *Curcuma longa* (Curcumin) – exhibits potent anti-inflammatory, antioxidant, and anti-proliferative activities.
- *Withania somnifera* (Withanolides) – enhances immunity, reduces oxidative stress, and exhibits apoptosis-inducing effects.
- *Panax ginseng* (Ginsenosides) – acts as an adaptogen, improves immune response, and enhances the efficacy of chemotherapy.

➢ **Advantages:**

- Convenient administration and storage stability.
- Ensures precise dosing and uniformity.
- Suitable for large-scale production and long-term therapy.

➢ **Example formulation:**

- *Curcumin capsule (500 mg)* has been used as an **adjunct therapy in colorectal cancer**, showing improved response to chemotherapy and reduction in inflammation-induced tumor progression.

4.3 Decoctions and Teas

Decoctions, infusions, and herbal teas represent traditional water-based formulations widely used for supportive care in cancer patients. These are prepared by boiling or steeping herbs to extract water-soluble phytoconstituents such as flavonoids, polyphenols, and alkaloids.

➢ **Examples of herbal teas:**

- *Camellia sinensis* (Green tea) – rich in catechins like EGCG that inhibit tumor proliferation and angiogenesis.
- *Zingiber officinale* (Ginger) – helps relieve nausea and vomiting associated with chemotherapy, while also exhibiting anti-inflammatory activity.
- *Ocimum sanctum* (Holy basil) – supports immune modulation and antioxidant defense.

➢ **Advantages:**

- Easy preparation and consumption.
- Provides hydration and antioxidant benefits.
- Acts as a mild supportive therapy during or after chemotherapy.

4.4 Syrups and Tonics

Herbal syrups and tonics are liquid formulations containing **concentrated aqueous or hydroalcoholic extracts** of medicinal plants. They are often enriched with natural sweeteners or flavoring agents to improve palatability, particularly for elderly and pediatric cancer patients.

➢ **Examples of commonly used ingredients:**

- *Withania somnifera* (Ashwagandha) – improves energy levels, reduces fatigue, and enhances immune response.
- *Viscum album* (Mistletoe) – exhibits immunostimulatory effects and has been used as an adjuvant in cancer therapy.
- *Curcuma longa* (Turmeric) – provides anti-inflammatory and antioxidant support during chemotherapy.

➢ **Advantages:**

- Rapid absorption and soothing effect.
- Suitable for patients with difficulty swallowing solid dosage forms.
- Acts as an immunomodulatory and restorative tonic during recovery phases.

4.5 Topical Formulations

Certain herbal preparations are designed for **external application**, especially for managing **skin cancers, radiation burns, and wound healing** post-surgery or radiotherapy.

- **Examples include:**

  - **Herbal ointments and creams** containing aloe vera, turmeric, and neem extracts to soothe inflammation and promote tissue regeneration.
  - **Essential oil-based gels** (e.g., tea tree oil, frankincense) exhibiting anti-proliferative and antimicrobial activity.

- **Advantages:**

  - Localized action with minimal systemic toxicity.
  - Useful for managing pain, inflammation, and lesions on the skin or mucous membranes

4.6 Parenteral and Injectable Formulations

Although less common, certain standardized herbal extracts are used as **injectable preparations** in cancer therapy, particularly in Europe and parts of Asia.

Example:

- *Viscum album* (Mistletoe extract) injections – used as adjuvant therapy in breast, lung, and colorectal cancers to enhance immune response and reduce chemotherapy-related fatigue.

Advantages:

- Rapid onset of action and systemic bioavailability.
- Effective in patients who cannot tolerate oral medications.

4.7 Novel Herbal Drug Delivery Systems

Recent advancements in pharmaceutics have led to the development of **nanotechnology-based herbal formulations** to overcome challenges of poor solubility and limited bioavailability of phytochemicals.

Examples include:

- **Curcumin nanoparticles and liposomes** – improve absorption, stability, and targeted delivery to tumor tissues.
- **Polymeric nanocarriers for resveratrol** – enhance controlled release and cytotoxic efficiency.
- **Phytosome formulations of green tea catechins** – increase cellular uptake and antioxidant potential.

Advantages:

- Improved pharmacokinetic properties and tissue targeting.
- Reduced toxicity and enhanced therapeutic index.
- Potential for use in precision oncology.

4.8 Injectable Formulations

Certain standardized herbal preparations, such as *Viscum album* (mistletoe) extracts, are available in injectable forms, especially in Europe, as supportive cancer therapy. These injections are administered under medical supervision to stimulate immune function, suppress tumor progression, and enhance quality of life.

- **Mechanism:** Acts as an immunostimulant and adjuvant to conventional therapies.
- **Clinical Relevance:** Widely used in integrative oncology centers for patients undergoing chemotherapy or radiotherapy.

4.9 Nanoparticle-Based Herbal Formulations

Recent advancements in nanotechnology have significantly improved the therapeutic potential of herbal compounds. Phytochemicals can be encapsulated into nanocarriers such as **liposomes**, **polymeric nanoparticles**, or **nanoemulsions** for **targeted tumor delivery**.

- **Advantages:** Enhanced solubility, bioavailability, controlled release, and reduced systemic toxicity.
- **Example:** Liposomal curcumin and resveratrol nanoparticles have shown promising results in preclinical models of breast, liver, and colon cancers.
- **Future Scope:** Nano-herbal formulations offer a novel platform for precision-based phytotherapy in oncology.

4.10 Combination Formulations

Combination formulations or **polyherbal extracts** are designed to exploit synergistic effects among multiple phytochemicals or between herbal and conventional chemotherapeutic agents.

- **Purpose:** To enhance anti-cancer efficacy, modulate immune responses, and reduce drug-induced toxicities.
- **Example:** A combined formulation of curcumin, epigallocatechin gallate (EGCG), and quercetin has demonstrated superior outcomes in inhibiting cancer cell proliferation and reducing oxidative stress in breast and colorectal cancers.
- **Advantages:** Multifactorial action, improved therapeutic outcomes, and better tolerability.

4.11 Standardization of Herbal Formulations

Standardization plays a crucial role in ensuring the **safety, efficacy, and reproducibility** of herbal medicines. Variability in phytochemical content due to differences in plant source, extraction method, and storage conditions can affect therapeutic outcomes. Therefore, standardized analytical techniques are essential.

- **Techniques Used:** High-Performance Liquid Chromatography (HPLC), Thin-Layer Chromatography (TLC), and spectrophotometric analysis for identification and quantification of bioactive compounds.
- **Objective:** To guarantee consistent pharmacological activity, eliminate adulteration, and ensure optimal patient safety.
- **Regulatory Need:** Development of pharmacopeial standards and Good Manufacturing Practices (GMP) for herbal formulations to promote global acceptance.

5. Mechanisms of Action of Herbal Medicines in Cancer

Herbal medicines exhibit potent anti-cancer properties through multiple biological mechanisms that collectively inhibit tumor growth, progression, and metastasis. These mechanisms target key molecular pathways involved in cancer cell survival, proliferation, and immune evasion.

5.1 Induction of Apoptosis

Apoptosis, or programmed cell death, is a natural process essential for eliminating damaged or abnormal cells. Many herbal compounds, such as curcumin, resveratrol, and withaferin A, activate caspase enzymes and mitochondrial pathways, leading to DNA fragmentation and cancer cell death. This helps selectively destroy malignant cells while sparing normal tissues.

5.2 Cell Cycle Arrest

Phytochemicals can interfere with the cell cycle, preventing uncontrolled cell division. By blocking the transition between the G1/S or G2/M phases, compounds such as quercetin and berberine suppress tumor cell proliferation and promote cellular repair mechanisms.

5.3 Inhibition of Angiogenesis

Tumor growth depends on the formation of new blood vessels (angiogenesis). Herbal constituents like ginsenosides and catechins inhibit vascular endothelial growth factor (VEGF) and other pro-angiogenic mediators, thereby restricting the nutrient and oxygen supply to cancer cells and limiting tumor expansion.

5.4 Antioxidant Activity

Oxidative stress plays a crucial role in DNA mutation and cancer initiation. Herbal antioxidants, including polyphenols and flavonoids, neutralize free radicals and reactive oxygen species (ROS), reducing oxidative damage and preventing carcinogenesis.

5.5 Immunomodulatory Action

Certain herbal medicines enhance the body's immune defense against cancer. Extracts from herbs like Withania somnifera and Astragalus membranaceus stimulate natural killer (NK) cells, activate T-lymphocytes, and regulate cytokine production, improving immune surveillance and tumor suppression.

5.6 Anti-Metastatic Effect

Metastasis, the spread of cancer to distant organs, is a major cause of cancer-related mortality. Herbal compounds such as curcumin and epigallocatechin gallate (EGCG) inhibit matrix metalloproteinases (MMPs) and key signaling pathways (e.g., NF-κB and MAPK), thereby blocking cancer cell invasion and migration.

6. Benefits and Challenges of Herbal Medicines in Cancer Therapy

Herbal medicines offer promising potential as complementary and integrative approaches in cancer management. While they provide several therapeutic advantages, certain limitations and challenges must be addressed to ensure their safe and effective clinical use.

6.1 Benefits

1. **Reduced Side Effects of Conventional Therapies:**

Herbal medicines can alleviate common adverse effects associated with chemotherapy and radiotherapy—such as nausea, fatigue, mucositis, and immunosuppression—thereby improving patient tolerance and treatment adherence.

2. **Improved Quality of Life:**

Many herbal formulations enhance appetite, energy levels, and emotional well-being, contributing to a better overall quality of life in cancer patients undergoing long-term therapy.

3. Synergistic Anti-Cancer Effects:

When used alongside conventional treatments, certain herbal compounds can potentiate the therapeutic effects of chemotherapeutic agents, promote apoptosis, and inhibit tumor resistance mechanisms, leading to enhanced treatment efficacy.

4. Accessibility and Cost-Effectiveness:

Herbal medicines are widely available, particularly in developing regions, and are generally more affordable compared to synthetic drugs, making them accessible to a larger population.

6.2 Challenges

1. Lack of Standardization and Quality Control:

Variations in plant species, growing conditions, and extraction techniques often lead to inconsistent concentrations of active phytochemicals, affecting the reproducibility and efficacy of herbal products.

2. Limited High-Quality Clinical Evidence:

Although numerous preclinical studies demonstrate anti-cancer potential, large-scale, randomized, and well-controlled clinical trials are still limited, hindering broader medical acceptance.

3. Potential Herb–Drug Interactions:

Herbal components may interact with chemotherapeutic agents or other medications, altering their metabolism and therapeutic outcomes, which can lead to reduced efficacy or increased toxicity.

4. Phytochemical Variability:

Environmental factors, cultivation methods, and post-harvest processing significantly influence the chemical composition of herbal materials, leading to variability in pharmacological activity.

Table 2 : Benefits and Challenges of Herbal Medicine in Oncology

Benefits	Challenges
Reduces chemotherapy and radiotherapy side effects	Lack of standardization and quality control
Improves patient quality of life	Limited large-scale clinical trials
Provides synergistic effects with conventional therapy	Potential herb–drug interactions
Cost-effective and easily available	Variability in phytochemical content

7. Conclusion

Herbal medicine offers a promising and holistic complementary approach to cancer management. The bioactive phytochemicals present in medicinal plants exhibit potent anti-cancer, antioxidant, and immunomodulatory properties, which can support conventional treatments by enhancing efficacy and reducing associated toxicity. Integrating herbal therapies with standard oncological practices may improve patient outcomes, minimize side effects, and enhance overall quality of life. However, the widespread clinical adoption of herbal medicine requires rigorous scientific validation through well-designed clinical trials, proper standardization of formulations, and comprehensive safety assessments. Future research should emphasize the identification of key bioactive compounds, elucidation of their molecular targets and mechanisms, and the development of evidence-based integrative cancer therapies that bridge traditional wisdom with modern medical science.

8. References

1. Qin W, Huang G, Chen Z, Zhang Y. Nanomaterials in targeting cancer stem cells for cancer therapy. *Front Pharmacol*. 2017;8:1. doi: 10.3389/fphar.2017.00001
2. Zhang LQ, Lv RW, Qu XD, et al. Aloesin suppresses cell growth and metastasis in ovarian cancer SKOV3 cells through the inhibition of the MAPK signaling pathway. *Anal Cell Pathol*. 2017;2017:1–6
3. Gorgzadeh A, Hheidari A, Ghanbarikondori P, et al. Investigating the properties and cytotoxicity of cisplatin-loaded nano-polybutylcyanoacrylate on breast cancer cells. *Asian Pacif J Can Biol*. 2023;8(4):345–350. doi: 10.31557/apjcb.2023.8.4.345-350
4. Heidari Z, Ghanbarikondori P, Mortazavi Mamaghani E, et al. Characteristics and cytotoxic effects of nano-liposomal paclitaxel on gastric cancer cells. *Asian Pac J Cancer Prev*. 2023;24(9):3291–3296. doi: 10.31557/APJCP.2023.24.9.3291
5. Ghanbarikondori P, Bagheri R, Saberian E, et al. Enhancing Cisplatin Delivery via Liposomal Nanoparticles for Oral Cancer Treatment. *Indian J Clin Biochem*. 2024. doi: 10.1007/s12291-024-01239-3
6. Saberian E, Jenča A, Petrášová A, Jenčová J, Jahromi RA, Seiffadini R. Oral cancer at a glance. *Asian Pacif J Can Biol*. 2023;8(4):379–386. doi: 10.31557/APJCB.2023.8.4.379-386
7. American Cancer Society. *Cancer Facts & figures 2016*. Atlanta, GA: American Cancer Society; 2016.
8. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin*. 2016;66(1):7–30. doi: 10.3322/caac.21332
9. Huang B, Zhang Y. Teaching an old dog new tricks: drug discovery by repositioning natural products and their derivatives. *Drug Discov Today*. 2022;27(7):1936–1944. doi: 10.1016/j.drudis.2022.02.007
10. Muhammad N, Usmani D, Tarique M, et al. The role of natural products and their multitargeted approach to treat solid cancer. *Cells*. 2022;11:2209.
11. Cadoná FC, Dantas RF, de Mello GH, Silva FP Jr. Natural products targeting into cancer hallmarks: an update on caffeine, theobromine, and (+)-catechin. *Crit Rev Food Sci Nutr*. 2021;62(26):7222–7241. doi: 10.1080/10408398.2021.1913091
12. Dickens E, Ahmed S. Principles of cancer treatment by chemotherapy. *Surgery*. 2018;36:134–138.
13. Liu S, Khan AR, Yang X, Dong B, Ji J, Zhai G. The reversal of chemotherapy-induced multidrug resistance by nanomedicine for cancer therapy. *J Control Release*. 2021;335:1–20. doi: 10.1016/j.jconrel.2021.05.012
14. Lee S, Rauch J, Kolch W. Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity. *Int J Mol Sci*. 2020;21(3):1102. doi: 10.3390/ijms21031102
15. Bashraheel SS, Domling A, Goda SK. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine. *Biomed Pharmacother*. 2020;125:110009. doi: 10.1016/j.biopha.2020.110009
16. Shaikh AM, Shrivastava DB, Dr KGA, Navale SD. Medicinal plants as potential source of anticancer agents: a review. *J Pharmacogn Phytochem*. 2016;5(2):291–295
17. Adriana Dehelean C, Marcovici I, Soica C, et al. Plant-derived anticancer compounds as new perspectives in drug discovery and alternative therapy. *Molecules*. 2021;26(4):1109. doi: 10.3390/molecules26041109
18. Khalid Abdulridha M, Al-Marzoqi AH, Raheem Lateef Al-Awsi G, et al. Anticancer effects of herbal medicine compounds and novel formulations: a literature review. *J Gastrointest Cancer*. 2020;51(3):765–773. doi: 10.1007/s12029-020-00385-0
19. Banerjee S, Nau S, Hochwald SN, et al. Anticancer properties and mechanisms of botanical derivatives. *Phytomedicine Plus*. 2023;3(1):100396.
20. Aryan H. The role of herbal medicine as anti-cancer medicine: from the claim to truth. *GMJ*. 2018;7:e1179. doi: 10.22086/gmj.v0i0.1179
21. Lee C-T, Huang Y-W, Yang C-H, et al. Drug delivery systems and combination therapy by using vinca alkaloids. *Curr Top Med Chem*. 2015;15(15):1491–1500. doi: 10.2174/1568026615666150414120547
22. Arora RD, Chen RJ, Menezes RG. *Vinca Alkaloid Toxicity*. StatPearls Publishing; 2023. PMID: 32491774.

23. Yan-Hua YANG, Jia-Wang MAO, Xiao-Li TAN. Research progress on the source, production, and anti-cancer mechanisms of paclitaxel. *Chinese J Nat Med*. 2020;18(12):890–897. doi: 10.1016/S1875-5364(20)60032-2
24. Chazin E, Reis R, Júnior W, Moor L, Vasconcelos T. An overview on the development of new potentially active camptothecin analogs against cancer. *Mini Reviews in Med Chem*. 2014;14(12):953–962. doi: 10.2174/1389557514666141029233037
25. Méresse P, Dechaux E, Monneret C, Bertounesque E. Etoposide: discovery and medicinal chemistry. *Curr. Med. Chem.* 2004;11(18):2443–2466. doi: 10.2174/0929867043364531
26. Kobayashi K, Ratain M. Pharmacodynamics and long-term toxicity of etoposide. *Cancer Chemother Pharmacol*. 2004;34(S1):S64–S68. doi: 10.1007/BF00684866
27. 29.Rivera G, Pui C, Santana V, Pratt C, Crist W. Epipodophyllotoxins in the treatment of childhood cancer. *Cancer Chemother Pharmacol*. 2004;34(S1):S89–S95. doi: 10.1007/BF00684870